(Q45229364)

11 December 2017

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients (English)

1 reference

11 December 2017

1

1 reference

11 December 2017

Chin B Eap

8

0 references

Thierry Buclin

object named as

Thierry Buclin

6

0 references

Laurent Arthur Decosterd

object named as

Laurent Decosterd

3

0 references

Amalio Telenti

7

object named as

Amalio Telenti

1 reference

11 December 2017

Catia Marzolini

2

1 reference

11 December 2017

Kerry Powell Golay

4

1 reference

11 December 2017

Pierre Baumann

5

1 reference

11 December 2017

19 January 2005

1 reference

European Journal of Clinical Pharmacology

11 December 2017

1 reference

11 December 2017

60

1 reference

11 December 2017

12

1 reference

11 December 2017

865-873

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-004-0855-8

11 December 2017

0 references

cites work

Efavirenz decreases methadone blood concentrations

1 reference

12 December 2020

Mdr1 limits CYP3A metabolism in vivo.

1 reference

12 December 2020

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1 reference

12 December 2020

Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

1 reference

12 December 2020

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

12 December 2020

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

1 reference

12 December 2020

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

12 December 2020

Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women

1 reference

12 December 2020

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

1 reference

12 December 2020

Oral absorption of the HIV protease inhibitors: a current update

1 reference

12 December 2020

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors

1 reference

12 December 2020

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

12 December 2020

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.

1 reference

12 December 2020

Pharmacokinetic enhancement of protease inhibitors.

1 reference

12 December 2020

Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry

1 reference

12 December 2020

Variability in activity of hepatic CYP3A4 in patients infected with HIV.

1 reference

12 December 2020

Cytochrome P450 3A: ontogeny and drug disposition

1 reference

12 December 2020

The drug efflux-metabolism alliance: biochemical aspects.

1 reference

12 December 2020

Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extractio

1 reference

12 December 2020

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

12 December 2020

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity

1 reference

12 December 2020

Grapefruit juice-drug interactions

1 reference

12 December 2020

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

1 reference

12 December 2020

Drug interactions of HIV protease inhibitors

1 reference

12 December 2020

10.1007/S00228-004-0855-8

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1029787343

0 references

Fatcat ID

release_42cfajtdxnblpbmjtm4l57og7u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/42cfajtdxnblpbmjtm4l57og7u

24 November 2022

mapped directly with Wikidata item

1 reference